Myriad debuts breast cancer diagnostic test for high-risk patients

By Elaine Rigoli

Tampa, Fla., Aug. 1 - Myriad Genetics, Inc. has introduced the BracAnalysis Rearrangement Test, a new molecular diagnostic test for breast cancer in the BracAnalysis family of products.

The added test detects rare, large rearrangements of the DNA in the BRCA1 and BRCA2 genes and will be performed for women with exceptionally high risk who have tested negative for sequence mutations and the common large rearrangements already included in Myriad's test, the company said in a news release.

Myriad will now conduct the BracAnalysis Rearrangement Test on patient samples where the individual's personal and family history is indicative of an exceptionally high level of risk, but the sample tests negative for BracAnalysis, the release said.

Myriad is a biopharmaceutical company located in Salt Lake City.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.